Immuno-Rheumatology Centre, St. Luke's International Hospital, St. Luke's International University, 9-1 Akashi-cho Chuo-ku, Tokyo, 104-8560, Japan.
Graduate School of Public Health, OMURA Susumu and Mieko Memorial St. Luke's Centre for Clinical Academia, St. Luke's International University, 5th Floor, 3-6-2 Tsukiji Chuo-ku, Tokyo, 104-0045, Japan.
Clin Rheumatol. 2020 Jun;39(6):1823-1827. doi: 10.1007/s10067-019-04848-z. Epub 2020 Feb 12.
The objective of the study is to evaluate the sensitivity of the new criteria for the classification of systemic lupus erythematosus (SLE), when applied to real SLE cases. We retrospectively reviewed the electronic medical records of 100 consecutive patients who visited St. Luke's International Hospital. Patients were included if they were clinically diagnosed as having SLE and excluded if they had other autoimmune disease or if they were less than 18 years old. Each patient was evaluated if they satisfied the American College of Rheumatology (ACR) 1997 classification criteria (1997 criteria), 2012 Systemic Lupus International Collaborating Clinics criteria (2012 criteria), or 2019 ACR/European League Against Rheumatism (EULAR) criteria. Among the 100 patients, the sensitivity of the 1997, 2012, and 2019 criteria was, 97, 99, and 92%, respectively. The total patient score with the 2019 criteria ranged from 12 to 44 (mean, 27.3). All patients who were classified as non-SLE with the 2019 criteria had an anti-nuclear antibody (ANA) titre of < 1:80. The 2019 criteria for SLE accomplished modestly high sensitivity in the real-world practice, but not as high as the 1997 and 2012 criteria. They possibly misclassify the real SLE cases as non-SLE, especially if patients have a low titre (< 1:80) of ANA.
本研究旨在评估新的系统性红斑狼疮(SLE)分类标准在真实 SLE 病例中的敏感性。我们回顾性分析了 100 例连续就诊于圣卢克国际医院的患者的电子病历。纳入标准为临床诊断为 SLE 的患者,排除标准为患有其他自身免疫性疾病或年龄小于 18 岁的患者。对每位患者进行评估,以确定其是否符合美国风湿病学会(ACR)1997 年分类标准(1997 标准)、2012 年系统性红斑狼疮国际合作临床标准(2012 标准)或 2019 年 ACR/欧洲抗风湿病联盟(EULAR)标准。在这 100 例患者中,1997 年、2012 年和 2019 年标准的敏感性分别为 97%、99%和 92%。2019 年标准的总患者评分范围为 12 至 44(平均 27.3)。所有被 2019 年标准归类为非 SLE 的患者的抗核抗体(ANA)滴度均<1:80。2019 年 SLE 标准在真实世界实践中具有适度高的敏感性,但不如 1997 年和 2012 年标准高。它们可能会错误地将真正的 SLE 病例归类为非 SLE,尤其是如果患者的 ANA 滴度较低(<1:80)。